DENTSPLY SIRONA Inc. (NASDAQ:XRAY – Free Report) – Investment analysts at Zacks Research cut their Q2 2026 earnings estimates for shares of DENTSPLY SIRONA in a report issued on Tuesday, May 26th. Zacks Research analyst Team now expects that the medical instruments supplier will post earnings per share of $0.36 for the quarter, down from their prior forecast of $0.38. Zacks Research has a “Hold” rating on the stock. The consensus estimate for DENTSPLY SIRONA’s current full-year earnings is $1.42 per share. Zacks Research also issued estimates for DENTSPLY SIRONA’s Q4 2026 earnings at $0.41 EPS, FY2026 earnings at $1.41 EPS, Q1 2027 earnings at $0.31 EPS, Q2 2027 earnings at $0.39 EPS, Q3 2027 earnings at $0.42 EPS, FY2027 earnings at $1.51 EPS, Q1 2028 earnings at $0.37 EPS and FY2028 earnings at $1.65 EPS.
A number of other equities research analysts have also issued reports on the stock. Citigroup assumed coverage on shares of DENTSPLY SIRONA in a report on Wednesday, April 15th. They issued a “sell” rating and a $10.00 price objective for the company. Weiss Ratings downgraded shares of DENTSPLY SIRONA from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Wednesday, May 6th. Barrington Research boosted their target price on shares of DENTSPLY SIRONA from $14.00 to $17.00 and gave the company an “outperform” rating in a report on Monday, March 2nd. Mizuho cut their price target on shares of DENTSPLY SIRONA from $16.00 to $14.00 and set a “neutral” rating for the company in a report on Wednesday, May 6th. Finally, Wells Fargo & Company lifted their price target on shares of DENTSPLY SIRONA from $12.00 to $13.00 and gave the company an “equal weight” rating in a research report on Friday, February 27th. Three equities research analysts have rated the stock with a Buy rating, eight have assigned a Hold rating and three have given a Sell rating to the stock. Based on data from MarketBeat, DENTSPLY SIRONA currently has an average rating of “Hold” and an average target price of $13.82.
DENTSPLY SIRONA Stock Down 2.2%
Shares of XRAY opened at $9.99 on Wednesday. DENTSPLY SIRONA has a 52-week low of $9.40 and a 52-week high of $17.09. The company has a quick ratio of 0.98, a current ratio of 1.53 and a debt-to-equity ratio of 1.52. The stock has a fifty day simple moving average of $11.36 and a two-hundred day simple moving average of $11.77. The company has a market capitalization of $2.00 billion, a PE ratio of -3.17, a price-to-earnings-growth ratio of 1.21 and a beta of 0.93.
DENTSPLY SIRONA (NASDAQ:XRAY – Get Free Report) last announced its quarterly earnings data on Tuesday, May 5th. The medical instruments supplier reported $0.27 EPS for the quarter, missing analysts’ consensus estimates of $0.28 by ($0.01). The company had revenue of $880.00 million for the quarter, compared to analysts’ expectations of $841.80 million. DENTSPLY SIRONA had a positive return on equity of 18.83% and a negative net margin of 17.06%.The business’s quarterly revenue was up .1% compared to the same quarter last year. During the same quarter in the previous year, the business posted $0.43 EPS. DENTSPLY SIRONA has set its FY 2026 guidance at 1.400-1.500 EPS.
Hedge Funds Weigh In On DENTSPLY SIRONA
Several institutional investors have recently bought and sold shares of the company. Eurizon Capital SGR S.p.A. purchased a new position in DENTSPLY SIRONA during the fourth quarter worth about $26,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. acquired a new position in DENTSPLY SIRONA during the 1st quarter worth approximately $26,000. Huntington National Bank raised its stake in shares of DENTSPLY SIRONA by 292.9% during the 3rd quarter. Huntington National Bank now owns 2,786 shares of the medical instruments supplier’s stock worth $35,000 after buying an additional 2,077 shares in the last quarter. Caitong International Asset Management Co. Ltd lifted its holdings in shares of DENTSPLY SIRONA by 337.9% in the 3rd quarter. Caitong International Asset Management Co. Ltd now owns 2,750 shares of the medical instruments supplier’s stock valued at $35,000 after buying an additional 2,122 shares during the period. Finally, Farther Finance Advisors LLC lifted its holdings in shares of DENTSPLY SIRONA by 119.1% in the 4th quarter. Farther Finance Advisors LLC now owns 3,773 shares of the medical instruments supplier’s stock valued at $43,000 after buying an additional 2,051 shares during the period. 95.70% of the stock is owned by institutional investors and hedge funds.
Insider Activity
In other news, Director James D. Forbes bought 5,000 shares of the firm’s stock in a transaction that occurred on Monday, March 9th. The stock was purchased at an average cost of $12.48 per share, with a total value of $62,400.00. Following the transaction, the director directly owned 10,000 shares in the company, valued at $124,800. This trade represents a 100.00% increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, Director Gregory T. Lucier purchased 15,000 shares of the business’s stock in a transaction on Monday, March 9th. The shares were purchased at an average cost of $12.45 per share, for a total transaction of $186,750.00. Following the transaction, the director owned 65,000 shares of the company’s stock, valued at $809,250. This trade represents a 30.00% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. Insiders bought a total of 70,000 shares of company stock valued at $956,437 over the last three months. Company insiders own 0.50% of the company’s stock.
About DENTSPLY SIRONA
Dentsply Sirona Inc (NASDAQ: XRAY) is a leading global manufacturer of professional dental products and technologies. The company, formed through the merger of Dentsply International and Sirona Dental Systems in February 2016, brings together a long heritage of innovation in dental care. Headquartered in Charlotte, North Carolina, Dentsply Sirona develops and markets a comprehensive range of dental consumables, laboratory products, and advanced imaging and CAD/CAM systems.
The company’s product portfolio spans preventive, restorative, orthodontic, endodontic and surgical care.
Read More
- Five stocks we like better than DENTSPLY SIRONA
- Banks Are Buying Back Stock Hand Over Fist, Including These 3 Names
- 2 Aluminum Stocks Poised for Big Tariff-Related Gains
- AutoZone’s Pullback Sets Up a Long-Term Buying Opportunity
- AST SpaceMobile’s June Launch Plan Puts Its 2026 Satellite Goal Back in Focus
Receive News & Ratings for DENTSPLY SIRONA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DENTSPLY SIRONA and related companies with MarketBeat.com's FREE daily email newsletter.
-logo-1200x675.png){kind=logo}
